Abstract 9P
Background
To evaluate clinicopathological features and prognosis in women with mucinous breast cancer (MBC), distinguishing between pure (PMC) and mixed (MMC) subtype.
Methods
A retrospective analysis of all 358 women with MBC treated at Vietnam National Cancer hospital from June 2015 to December 2020. PMC was defined by ≥ 90% mucinous components.
Results
We identified 358 women with MBC (245 PMC and 113 MMC) representing 2.7% of all 13,254 breast cancer patients. The proportion of stage I, II, III and IV were 34.9%, 50.8%, 10.4% and 3.9% respectively. 95.3% of patients were hormone receptor positive. The rate of HER2 overexpression is 12%, and only 1.4% of patients was treated with anti-HER2. 193 patients (53.9%) had chemotherapy (CT), including 55 patients (15.4%) treated in neoadjuvant setting. Among those received neoadjuvant CT, only 3 patients (5.5%) achieved pCR. Meanwhile, the rates of partial response, stable disease and progressive disease were 50.8%, 38.2% and 5.5% respectively. PMC patients were older (54.4±13.3 vs 51.1±13.1 years), had lower Ki67 expression, lower incidence of nodal metastasis (N+) than MMC patients (p values <0.05). At median follow-up of 58 months, the 5-year overall survival rate of non-metastatic patients was 86.6%. Univariate analysis revealed that significant factors for poorer OS were MMC subtype (p=0.02), large tumor size (T) (p<0.001), N+ (p<0.001), HER2 overexpression (p<0.001), PR negative (p=0.02), and high Ki67 (p=0.02). Multivariate analysis showed nodal metastasis (N+) to be the most significant prognostic factor (HR=3.3; 95%CI 1.5-7.1), followed by high T stage (HR=2.9; 95%CI 1.4-6.3), HER2 overexpression (HR=2.5; 95%CI 1.2-5.3) and MMC subtype (HR=1.9; 95%CI 1.0-3.9). Amongst 245 patients with stage T1-2N0M0, 40.8% of those treated with CT related to worse overall survival (5-year OS 88.0% vs 95.6%, p=0.04).
Conclusions
The majority of MBC are luminal subtypes and associated with good prognosis. Poor prognostic factors of women with MBC are high T, N stage, HER2 overexpression and MMC subtype. Chemotherapy in stage T1-2N0M0 brings a worse survival outcome compared to endocrine therapy. Given the low response rate to neoadjuvant CT, upfront surgery is appropriate for MBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract